Recent executive action has advanced partial cannabis rescheduling under the Controlled Substances Act. In late April 2026 the Department of Justice and DEA placed FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective immediately, following a December 2025 executive order directing expedited rulemaking. A new administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III is now scheduled to begin June 29 and conclude no later than July 15, 2026. These steps replace earlier proceedings and create a defined timeline for potential full federal reclassification, which would affect tax treatment, research access, and interstate commerce rules. Traders are monitoring the hearing outcome and any subsequent final rule for resolution of date-specific markets.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$758,943 ปริมาณ
Mar 31, 2026
June 30
2%
December 31
24%
$758,943 ปริมาณ
June 30
$337,208 ปริมาณ
2%
December 31
$156,853 ปริมาณ
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive action has advanced partial cannabis rescheduling under the Controlled Substances Act. In late April 2026 the Department of Justice and DEA placed FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective immediately, following a December 2025 executive order directing expedited rulemaking. A new administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III is now scheduled to begin June 29 and conclude no later than July 15, 2026. These steps replace earlier proceedings and create a defined timeline for potential full federal reclassification, which would affect tax treatment, research access, and interstate commerce rules. Traders are monitoring the hearing outcome and any subsequent final rule for resolution of date-specific markets.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Feb 7, 2026, 5:04 PM ET
ปริมาณการซื้อขาย
$758,943วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive action has advanced partial cannabis rescheduling under the Controlled Substances Act. In late April 2026 the Department of Justice and DEA placed FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective immediately, following a December 2025 executive order directing expedited rulemaking. A new administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III is now scheduled to begin June 29 and conclude no later than July 15, 2026. These steps replace earlier proceedings and create a defined timeline for potential full federal reclassification, which would affect tax treatment, research access, and interstate commerce rules. Traders are monitoring the hearing outcome and any subsequent final rule for resolution of date-specific markets.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$758,943วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent executive action has advanced partial cannabis rescheduling under the Controlled Substances Act. In late April 2026 the Department of Justice and DEA placed FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective immediately, following a December 2025 executive order directing expedited rulemaking. A new administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III is now scheduled to begin June 29 and conclude no later than July 15, 2026. These steps replace earlier proceedings and create a defined timeline for potential full federal reclassification, which would affect tax treatment, research access, and interstate commerce rules. Traders are monitoring the hearing outcome and any subsequent final rule for resolution of date-specific markets.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย